[99mTc]HYNIC-RGD for imaging integrin αvβ3 expression

Nuclear Medicine and Biology

Volumn 33, Issue 8, 2006, Pages 945-952

  Decristoforo, Clemens ^a   Faintuch Linkowski, Bluma ^b   Rey, Ana ^c   von Guggenberg, Elisabeth ^a   Rupprich, Marco ^a   Hernandez Gonzales, Ignacio ^d   Rodrigo, Teodoro ^b   Haubner, Roland ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^c UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^d Centro de Isotopos Cuba   (Cuba)

Author keywords

v 3; HYNIC; RGD; Technetium 99m

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; INTEGRIN; SULFONIC ACID DERIVATIVE; TECHNETIUM 99M; 6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID; 6-HYDRAZINOPYRIDINE-3-CARBOXYLIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; DIAGNOSTIC AGENT; HYDRAZINE DERIVATIVE; NICOTINIC ACID DERIVATIVE; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EVALUATION; HUMAN; HUMAN CELL; IMAGING; ISOTOPE LABELING; LIGAND BINDING; LIPOPHILICITY; LIVER; LUNG SMALL CELL CANCER; MELANOMA CELL; MEMBRANE TRANSPORT; MOUSE; MUSCLE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URINARY EXCRETION; ANIMAL; BAGG ALBINO MOUSE; DRUG STABILITY; LUNG TUMOR; MALE; METABOLISM; PROTEIN BINDING; SCINTISCANNING; SMALL CELL CARCINOMA; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; DRUG STABILITY; HUMANS; HYDRAZINES; INTEGRIN ALPHAVBETA3; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NICOTINIC ACIDS; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; PROTEIN BINDING; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33751336092     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.09.001     Document Type: Article

References (27)

1. Riccabona G., and Decristoforo C. Peptide targeted imaging of cancer. Cancer Biother Radiopharm 18 (2003) 675-687
2. Heppeler A., Froidevaux S., Eberle A.N., and Maecke H.R. Receptor targeting for tumour localisation and therapy with radiopeptides. Curr Med Chem 7 (2000) 971-994
3. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24 (2003) 389-427
4. Haubner R., and Wester H.J. Radiolabeled tracers for imaging of tumour angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 10 (2004) 1439-1455
5. 3-Integrin imaging: a new approach to characterize angiogenesis?. Eur J Nucl Med Mol Imaging 33 Suppl 13 (2006) 54-63
6. Felding-Habermann B., Mueller B.M., Romerdahl C.A., and Cheresh D.A. Involvement of integrin alpha V gene expression in human melanoma tumourigenicity. J Clin Invest 89 (1992) 2018-2022
7. Aumailley M., Gurrath M., Muller G., Calvete J., Timpl R., and Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 291 (1991) 50-54
8. 3 integrin antagonists: a new class of tracers for tumour targeting. J Nucl Med 40 (1999) 1061-1071
9. 18F]galacto-RGD. PLoS Med 2 (2005) 29
10. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 99 (1999) 2235-2268
11. 111In-octreotide. J Nucl Med 41 (2000) 1114-1119
12. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (N alpha-His)acetic acid-modified [d-Glu1]-minigastrin. Bioconjug Chem 15 (2004) 864-871
13. van Hagen P.M., Breeman W.A., Bernard H.F., Schaar M., Mooij C.M., Srinivasan A., et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 90 (2000) 186-198
14. Decristoforo C., and Mather S.J. 99m-Technetium labelled peptide-HYNIC conjugates. The effects of lipophilicity and stability on biodistribution. Nucl Med Biol 26 (1999) 389-396
15. 99mTc-EDDA/HYNIC-TOC). J Lab Comp Radiopharm 46 (2003) 307-318
16. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61 (2001) 1781-1785
17. Sivolapenko G.B., Skarlos D., Pectasides D., Stathopoulou E., Milonakis A., Sirmalis G., et al. Related imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 25 (1998) 1383-1389
18. 99mTc-labeled Arg-Gly-Asp (RGD) peptide in rats with ischemic acute renal failure. J Am Soc Nephrol 7 (1996) 2682-2688
19. 3 expression. Nuklearmedizin 43 (2004) 26-32
20. Su Z.F., Liu G., Gupta S., Zhu Z., Rusckowski M., and Hnatowich D.J. In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumour imaging. Bioconjug Chem 13 (2002) 561-570
21. 3 integrin for tumour imaging". Bioconjug Chem 14 (2003) 274
22. Su Z.F., He J., Rusckowski M., and Hnatowich D.J. In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands. Nucl Med Biol 30 (2003) 141-149
23. Janssen M., Oyen W.J., Massuger L.F., Frielink C., Dijkgraaf I., Edwards D.S., et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumour targeting. Cancer Biother Radiopharm 17 (2002) 641-646
24. 18F-galacto-RGD in cancer patients. J Nucl Med 46 (2005) 1333-1341
25. Villanueva F.S. Molecular images of neovascularization: art for art's sake or form with a function?. Circulation 111 (2005) 3188-3191
26. 3 integrin after murine hindlimb ischemia. Circulation 111 (2005) 3255-3260
27. 18F-galacto-RGD. J Nucl Med 46 (2005) 184-189